# SGLT2i Therapy in Islet Transplantation (SIT)

> **NCT07228195** · PHASE4 · NOT_YET_RECRUITING · sponsor: **University of Minnesota** · enrollment: 40 (estimated)

## Conditions studied

- Partial Islet Function
- TPIAT
- Diabetes

## Interventions

- **DRUG:** Empagliflozin 25 MG Oral Tablet
- **DRUG:** Empagliflozin 10 MG Oral Tablet [Jardiance]

## Key facts

- **NCT ID:** NCT07228195
- **Lead sponsor:** University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-15
- **Primary completion:** 2028-12-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07228195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07228195, "SGLT2i Therapy in Islet Transplantation (SIT)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07228195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*